I presume from the PR that Eliquis hit all endpoints on an ITT basis; however, given the way JNJ and Bayer presented the Xarelto data, your question is a reasonable one to ask.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”